Ronald Gelbman has a longstanding career in the pharmaceutical industry, where he has made significant contributions. Born in 1948, he became the Interim CEO of Haemonetics Corporation on September 30, 2015, stepping in after the previous CEO left to pursue...

Ronald Gelbman has a longstanding career in the pharmaceutical industry, where he has made significant contributions. Born in 1948, he became the Interim CEO of Haemonetics Corporation on September 30, 2015, stepping in after the previous CEO left to pursue other opportunities. Gelbman has been a member of Haemonetics' Board of Directors since 2000 and served as their Interim CEO for a short period until May 2016, balancing his executive responsibilities while remaining an influential board member. Before this role, he retired from Johnson & Johnson in 2000, where he held key positions, including Worldwide Chairman of the Pharmaceuticals, Diagnostics, and Health Systems Groups. His extensive experience at one of the world's largest healthcare companies sets a solid groundwork for his leadership style. Not only is he active in corporate governance, but he is also on several boards, including advisories for Cambryn Biologics and SunTrust Southwest Florida. Throughout his career, Gelbman demonstrated a commitment to aligning business strategies with innovative healthcare solutions.